Browsing by Subject "A61K 38/21"

Now showing items 1-8 of 8

    • Interferon dosage form and method therefor 
      Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2002-04-16)
      Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
    • Treatment of autoimmune disorders with oral interferon 
      Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-12-08)
      Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's ...
    • Treatment of bacterial infection with oral interferon-α 
      Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-10-06)
      Bacterial infections are treated by the administration of alpha-interferon at a dosage of from about 0.1 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The ...
    • Treatment of hyperallergenic response with oral interferon 
      Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1999-03-16)
      Hyperallergenic conditions are treated by the administration of interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. ...
    • Treatment of immuno-resistant disease with low-dose interferon 
      Cummins, Joseph M., Jr. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1991-05-28)
      Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
    • Treatment of neoplastic disease with oral interferon 
      Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-10-20)
      Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and ...
    • Treatment of viral disease with oral interferon-α 
      Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-11-03)
      Viral infections are treated by the administration of alpha-interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The ...
    • Use of vitelline protein B as a microencapsulating additive 
      Ficht, Allison R.; Carson, Kenneth; Sheffield, Cynthia; Waite, John Herbert (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2021-03-23)
      The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended ...